^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK4 inhibitor

    Related drugs:
    3d
    FUTURE: Aspects of Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients - Focusing on Geriatric Screening (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Region Jönköping County
    New trial • HEOR
    7d
    ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (clinicaltrials.gov)
    P3, N=240, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 mutation
    |
    everolimus • dexamethasone • Orserdu (elacestrant)
    7d
    Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor. (PubMed, J Med Chem)
    Central to our strategy were efficiency-based optimization (LipE and LipMetE), structure-based drug design, and molecular dynamics simulation. The culmination of these efforts resulted in the discovery of PF-07220060 (atirmociclib), which possessed high potency and levels of selectivity for CDK4 over CDK6 that translated to minimal impact on neutrophils while driving efficacy in a mouse ZR75-1 xenograft model.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK6 (Cyclin-dependent kinase 6)
    |
    HR positive • HER-2 negative
    |
    atirmociclib (PF-07220060)
    10d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, Case Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=29 --> 14
    Enrollment closed • Enrollment change
    |
    Verzenio (abemaciclib)
    10d
    Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Lucentis (ranibizumab) • Simponi (golimumab)
    14d
    A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants (clinicaltrials.gov)
    P1, N=35, Completed, Pfizer | Not yet recruiting --> Completed
    Trial completion
    |
    atirmociclib (PF-07220060)
    14d
    Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (clinicaltrials.gov)
    P1, N=72, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    atirmociclib (PF-07220060)
    14d
    A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (clinicaltrials.gov)
    P1, N=28, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • atirmociclib (PF-07220060)
    16d
    FN-1501 Synergistically Enhances Almonertinib Efficacy in EGFR-TKI-Resistant Lung Adenocarcinoma through Ferroptosis Induction. (PubMed, Anticancer Agents Med Chem)
    FN-1501 exhibits significant antitumor activity and, when combined with Alm, effectively reverses EGFR-TKI resistance by inducing ferroptosis, highlighting its potential for clinical application.
    Journal
    |
    NCOA4 (Nuclear Receptor Coactivator 4)
    |
    Ameile (aumolertinib) • FN-1501
    18d
    OP-1250-002: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Olema Pharmaceuticals, Inc. | Trial completion date: Jul 2025 --> Mar 2026 | Trial primary completion date: Jan 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Ibrance (palbociclib) • palazestrant (OP-1250)
    23d
    A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    fulvestrant • Jingzhuda (entinostat)
    29d
    NCI-2020-05682: Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=700, Recruiting, Roswell Park Cancer Institute | Trial completion date: Jul 2030 --> Jul 2035
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative